Lisinopril hydrochlorothiazide pharmacology
Pro Research Analysisby 
Searched over 200M research papers
Lisinopril and Hydrochlorothiazide Pharmacology Overview
Lisinopril and hydrochlorothiazide are often combined to treat hypertension, offering complementary mechanisms of action and enhanced blood pressure control. Their pharmacological profiles and interactions have been well studied in both healthy volunteers and patients with hypertension.
Mechanism of Action and Pharmacodynamics
Lisinopril: ACE Inhibition and Blood Pressure Reduction
Lisinopril is an orally active angiotensin-converting enzyme (ACE) inhibitor. It works by blocking the conversion of angiotensin I to angiotensin II, leading to reduced levels of angiotensin II and aldosterone, increased plasma renin activity, and a gradual reduction in blood pressure. Lisinopril does not significantly affect heart rate or cardiovascular reflexes and is effective in lowering both systolic and diastolic blood pressure. It also has natriuretic properties and can increase cardiac output in patients with heart failure Gomez1987Chase1989.
Hydrochlorothiazide: Diuretic Effect
Hydrochlorothiazide is a thiazide diuretic that lowers blood pressure by promoting sodium and water excretion, reducing blood volume, and decreasing peripheral vascular resistance. When combined with lisinopril, it enhances the antihypertensive effect Gomez1987Chase1989Chrysant1994.
Pharmacokinetics of Lisinopril and Hydrochlorothiazide Combination
Absorption and Bioavailability
Lisinopril has a bioavailability of about 25%, which is not significantly affected by food, age, or coadministration with hydrochlorothiazide Gomez1987Chase1989. Hydrochlorothiazide is also well absorbed, and both drugs reach peak serum concentrations within hours after oral administration—lisinopril at 6–8 hours and hydrochlorothiazide at 2–6 hours Gomez1987Tian2007Swaisland1991+1 MORE.
Distribution and Elimination
Lisinopril is not metabolized and is excreted unchanged in the urine, with an elimination half-life of about 12–13 hours. Hydrochlorothiazide is also eliminated primarily by the kidneys. Both drugs show linear elimination characteristics, and steady-state concentrations are achieved after a few days of dosing Gomez1987Tian2007Mucklow1995+1 MORE.
Pharmacokinetic Interactions
Multiple studies show that coadministration of lisinopril and hydrochlorothiazide does not result in clinically significant pharmacokinetic interactions. The pharmacokinetic parameters (such as peak concentration, area under the curve, and time to peak) for each drug remain largely unchanged when given together, whether as separate tablets or in a fixed-dose combination Gomez1987Swaisland1991Mucklow1995+2 MORE. Bioequivalence studies confirm that generic and reference formulations of the combination are similar in both fasting and postprandial states, though food can reduce lisinopril exposure by about 20–25% .
Special Populations
In elderly and renally impaired patients, higher serum concentrations of both drugs are observed, but this does not lead to greater blood pressure reduction. The extent of drug accumulation is similar across age groups, and no additional dosage adjustments are needed beyond those recommended for the individual drugs .
Clinical Efficacy and Safety
The combination of lisinopril and hydrochlorothiazide provides greater blood pressure reduction than either drug alone, with the best results seen at low doses of both agents. The combination is generally well tolerated, with a safety profile similar to monotherapy. Metabolic side effects are minimal at lower doses, and the risk of hypokalemia, hyperglycemia, or hyperuricemia is reduced compared to higher doses of hydrochlorothiazide alone Gomez1987Chase1989Chrysant1994.
Conclusion
Lisinopril and hydrochlorothiazide, when used together, offer effective and well-tolerated blood pressure control. Their pharmacokinetic profiles are stable and predictable, with no significant interactions when coadministered. The combination is suitable for a wide range of patients, including the elderly and those with renal impairment, and is associated with minimal metabolic side effects at recommended doses Gomez1987Tian2007Swaisland1991+6 MORE.
Sources and full results
Most relevant research papers on this topic